tbuckley/cabot-search huggingface dataset:
Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial
Authors: D. J. Klein, D. Foster, P. M. Walker, S. M. Bagshaw, H. Mekonnen, M. Antonelli
Journal: Intensive Care Medicine (2018)

The EUPHRATES trial examined the impact of polymyxin B hemoperfusion (PMX) on mortality in patients with septic shock and endotoxemia, defined as EAA ≥ 0.60. No difference was found in 28-day all-cause mortality. However, the trial showed that in some patients with septic shock the burden of endotoxin activity was extreme (EAA ≥ 0.9). In a post hoc analysis, we evaluated the impact of PMX use in patients with septic shock and endotoxin activity measured between 0.6–0.89. Post-hoc analysis of the EUPHRATES trial for the 194 patients with EAA ≥ 0.6–0.89 who completed two treatments (PMX or sham). The primary end point was mortality at 28 days adjusted for APACHE II score and baseline mean arterial pressure (MAP). Additional end points included changes in MAP, cumulative vasopressor index (CVI), median EAA reduction, ventilator-free days (VFD), dialysis-free days (DFD) and hospital length of stay. Subpopulations analyzed were site and type of infection and those with norepinephrine dose > 0.1 mcg/kg/min at baseline. At 28 days, 23 patients of 88 (26.1%) in the PMX group died versus 39 of 106 (36.8%) in the sham group [risk difference 10.7%, OR 0.52, 95% CI (0.27, 0.99), P = 0.047]. When unadjusted for baseline variables, P = 0.11. The 28-day survival time in the PMX group was longer than for the sham group [HR 0.56 (95% CI 0.33, 0.95) P = 0.03]. PMX treatment compared with sham showed greater change in MAP [median (IQR) 8 mmHg (− 0.5, 19.5) vs. 4 mmHg (− 4.0, 11) P = 0.04] and VFD [median (IQR) 20 days (0.5, 23.5) vs. 6 days (0, 20), P = 0.004]. There were no significant differences in other end points. There was a significant difference in mortality in PMX-treated patients with no bacterial growth on culture [PMX, 6/30 (20%) vs. sham, 13/31 (41.9%), P = 0.005]. The median EAA change in the population was − 12.9% (range: increase 49.2%–reduction 86.3%). The mortality in the above median EAA change group was PMX: 6/38 (15.7%) vs. sham 15/49 (30.6%), P = 0.08. These hypothesis-generating results, based on an exploratory post hoc analysis of the EUPHRATES trial, suggest measurable responses in patients with septic shock and an EAA ≥ 0.6 to 0.89 on changes in mean arterial pressure, ventilator-free days and mortality. Clinicaltrials.gov Identifier: NCT01046669. Funding Spectral Medical Incorporated.
Development of an ICU discharge instrument predicting psychological morbidity: a multinational study
Authors: A. Milton, A. Schandl, I. W. Soliman, K. Meijers, M. van den Boogaard, I. M. Larsson, C. Brorsson, U. Östberg, M. Oxenbøll-Collet, J. Savilampi, S. Paskins, M. Bottai, P. V. Sackey
Journal: Intensive Care Medicine (2018)

To develop an instrument for use at ICU discharge for prediction of psychological problems in ICU survivors.Multinational, prospective cohort study in ten general ICUs in secondary and tertiary care hospitals in Sweden, Denmark and the Netherlands. Adult patients with an ICU stay ≥ 12 h were eligible for inclusion. Patients in need of neurointensive care, with documented cognitive impairment, unable to communicate in the local language, without a home address or with more than one limitation of therapy were excluded. Primary outcome was psychological morbidity 3 months after ICU discharge, defined as Hospital Anxiety and Depression Scale (HADS) subscale score ≥ 11 or Post-traumatic Stress Symptoms Checklist-14 (PTSS-14) part B score > 45.A total of 572 patients were included and 78% of patients alive at follow-up responded to questionnaires. Twenty percent were classified as having psychological problems post-ICU. Of 18 potential risk factors, four were included in the final prediction model after multivariable logistic regression analysis: symptoms of depression [odds ratio (OR) 1.29, 95% confidence interval (CI) 1.10-1.50], traumatic memories (OR 1.44, 95% CI 1.13-1.82), lack of social support (OR 3.28, 95% CI 1.47-7.32) and age (age-dependent OR, peak risk at age 49-65 years). The area under the receiver operating characteristics curve (AUC) for the instrument was 0.76 (95% CI 0.70-0.81).We developed an instrument to predict individual patients' risk for psychological problems 3 months post-ICU, http://www.imm.ki.se/biostatistics/calculators/psychmorb/ . The instrument can be used for triage of patients for psychological ICU follow-up.The study was registered at clinicaltrials.gov, NCT02679157.
Abstract 19917: Metabolic Effects of Metformin in Chronic Heart Failure Patients are Mediated by Gut Incretin Release
Authors: Vojtech Melenovsky, Eva Stolarikova, Lenka Belinova, Katerina Velebova, Marketa Szegetova, Ondrej Kuda, Jan Kopecky, Terezie Pelikanova
Journal: Circulation (2017)

Introduction: Metformin (MET) use in diabetic patients with heart failure (HF) is associated with better outcomes, but mechanisms of MET-mediated cardioprotection are unexplained. Hypothesis: we hy...
Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome
Authors: Tenzin Gayden, Fernando E. Sepulveda, Dong-Anh Khuong-Quang, Jonathan Pratt, Elvis T. Valera, Alexandrine Garrigue, Susan Kelso, Frank Sicheri, Leonie G. Mikael, Nancy Hamel, Andrea Bajic, Rola Dali, Shriya Deshmukh, Dzana Dervovic, Daniel Schramek, Frédéric Guerin, Mikko Taipale, Hamid Nikbakht, Jacek Majewski, Despina Moshous, Janie Charlebois, Sharon Abish, Christine Bole-Feysot, Patrick Nitschke, Brigitte Bader-Meunier, David Mitchell, Catherine Thieblemont, Maxime Battistella, Simon Gravel, Van-Hung Nguyen, Rachel Conyers, Jean-Sebastien Diana, Chris McCormack, H. Miles Prince, Marianne Besnard, Stephane Blanche, Paul G. Ekert, Sylvie Fraitag, William D. Foulkes, Alain Fischer, Bénédicte Neven, David Michonneau, Geneviève de Saint Basile, Nada Jabado
Journal: Nature Genetics (2018)
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Authors: Florence Duffaud, Olivier Mir, Pascaline Boudou-Rouquette, Sophie Piperno-Neumann, Nicolas Penel, Emanuelle Bompas, Corinne Delcambre, Elsa Kalbacher, Antoine Italiano, Olivier Collard, Christine Chevreau, Esma Saada, Nicolas Isambert, Jessy Delaye, Camille Schiffler, Corinne Bouvier, Vincent Vidal, Sylvie Chabaud, Jean-Yves Blay
Journal: The Lancet Oncology (2018)
THU0140 Effects of statin-treatment on coronary plaques in patients with inflammatory joint diseases
Authors: M. Svanteson, S. Rollefstad, N.E. Kløw, E. Ikdahl, J. Sexton, Y. Haig, A.G. Semb
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Statins have an established preventive effect on coronary artery disease in the general population. The effect of statins on coronary plaque progression and characteristics in patients with inflammatory joint diseases (IJD) is unknown. <h3>Objectives</h3> Our aim was to evaluate the change in coronary atherosclerosis in long-term statin-treated patients with IJD. <h3>Methods</h3> Sixty-eight patients with IJD and carotid artery plaque, underwent coronary computed tomography angiography before and after 4.7 (range 4.0–6.0) years of statin treatment. The treatment target for low density lipoprotein cholesterol (LDL-c) was ≤1.8 mmol/L. Changes in coronary artery calcification (CAC) and coronary artery plaque volume (calcified, mixed/soft and total) from baseline to follow-up were assessed using the 17-segment model of the American Heart Association. Linear regression analysis was used to identify predictors of atherosclerotic progression. <h3>Results</h3> Coronary plaques were present in 42% of the patients at baseline and in 51% at follow up. Mean CAC score increased with 173±284, calcified plaque volume with 39.4±78.3 mm<sup>3</sup> and total plaque volume with 22.8±54.6 mm<sup>3</sup> (p≤0.01, for all) (figure 1). Mean mixed/soft plaque volume decreased with −10.4±27.5 mm<sup>3</sup> (p≤0.01). At follow-up, 51% of the patients had obtained LDL-c treatment target. Compared to patients above LDL-c target, patients with an LDL-c ≤1.8 mmol/L experienced reduced median progression of both CAC (21<sup>2–143</sup> vs. 69 [16–423], p&lt;0.01) and total plaque volume (0.08 [−1.0–13.9] vs. 13.0 [0.0–60.8], p=0.02) (table 1). <h3>Conclusions</h3> We revealed a progression of atherosclerotic plaque volume in statin-treated patients with IJD, mainly due to calcifications. However, soft, unstable plaques were reduced, probably as a result of an alteration in plaque composition from mixed/soft plaques into calcified plaques. Patients with recommended LDL-c levels at follow-up experienced a reduced atherosclerotic progression compared to patients with LDL-c levels above the treatment target. Our results support the importance of treatment to guideline recommended lipid targets in IJD patients. <h3>Disclosure of Interest</h3> None declared
Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Authors: Thierry Facon, Shaji K. Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Joseph R. Mace, Tahamtan Ahmadi, Christopher Chiu, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, Ming Qi, Saad Z. Usmani
Journal: Blood (2018)
A tricky case of pancreatic arteriovenous malformation: the role of endoscopic ultrasound in the diagnosis of this rare condition
Authors: Ilenia Barbuscio, Alberto Fantin, Matteo Ghisa, Lucia Moletta, Cosimo Sperti, Fabio Farinati
Journal: Endoscopy (2018)

A 77-year-old man was referred to our hospital for further evaluation of a symptomatic pancreatic mass.
Abstract B21: Epigenetic modifiers MLL1 and JMJD3 regulate neuroblastoma tumorigenicity by maintaining a cancer stem cell-like population
Authors: Saurabh Agarwal, Julie Tomolonis, Sanjeev Vasudevan, Jason Shohet
Journal: Cancer Research (2018)

Abstract High-risk neuroblastoma (NB) represents a major clinical challenge in pediatric oncology. Despite significant dose escalation of intense therapies, long-term survival for NB patients remains poor (&amp;lt;45%), and the disease accounts for almost 15% of all pediatric cancer deaths. Relapse of metastatic, drug-resistant disease and treatment-related toxicities mandates the development of new therapeutic strategies. Recently, we discovered a highly tumorigenic, chemoresistant, and self-renewing subpopulation in NB with features similar to cancer stem cells (CSCs). This G-CSF receptor (CD114)-expressing subpopulation can escape initial therapy and cause aggressively invasive relapsed disease. Therefore, developing direct targeting strategies and understanding for the molecular mechanisms maintaining this NB CSC-like subpopulation is essential to delineate effective therapeutics for NB patients. By using siRNA screening approach and low-density pathway arrays, we found that the epigenetic regulators mixed-lineage leukemia-1 (MLL1; KMT2A; a H3K4me3 methyltransferase) and Jumonji D3 (JMJD3; KDM6B; a H3K27me3 demethylase) are important epigenetic regulators for NB proliferation and growth. Interestingly, we found that epigenetic regulators MLL1 and JMJD3 are aberrantly expressed in CD114+ subpopulation and regulate the expression of the G-CSF receptor gene (CSF3R) itself, by maintaining active histone modifications at the promoter locus. Inhibition of MLL1 and JMJD3 with specific small-molecule inhibitors reverses the histone patterns at CSF3R promoter and blocks gene expression, induces apoptosis selectively in CD114+ cells, and inhibits overall NB proliferation in vitro. Furthermore, inhibiting MLL1 and JMJD3 leads to dramatic tumor regression (p&amp;lt;0.001) and reduction in incidences of metastasis (p&amp;lt;0.001) in vivo. Most interestingly, both of these inhibitors increase the overall survival of the treated mice in vivo. As expected, reduction in tumor size was significantly correlated with the reduction in tumor CD114+ cells. Taken together, these data highlight that: a) neuroblastoma is maintained by the complex interplay of epigenetic modifiers, and b) direct targeting of these epigenetic modifiers and combining this approach with current therapy is a novel therapeutic approach to high-risk NB. Citation Format: Saurabh Agarwal, Julie Tomolonis, Sanjeev Vasudevan, Jason Shohet. Epigenetic modifiers MLL1 and JMJD3 regulate neuroblastoma tumorigenicity by maintaining a cancer stem cell-like population [abstract]. In: Proceedings of the AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; 2017 Dec 3-6; Atlanta, Georgia. Philadelphia (PA): AACR; Cancer Res 2018;78(19 Suppl):Abstract nr B21.
SP0124 Physical activity and exercise: opportunities and challenges
Authors: M. Englund
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> Osteoarthritis (OA) is a steadily growing public health concern in particular as there is still a lack of curative therapeutic options in a biological sense. Thus, <i>prevention</i> of OA becomes an increasingly important topic. Physical activity, and exercise are among the key modifiable risk factors associated with OA. Joints are built to be used, but overuse and joint injuries are also linked with incident OA. This presentation will provide some key opportunities with exercise to maintain joint health, but also the challenges when the window of opportunity is exceeded. <h3>Disclosure of Interest</h3> None declared
mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases
Authors: Simon C. Johnson, Frank Martinez, Alessandro Bitto, Brenda Gonzalez, Cagdas Tazaerslan, Camille Cohen, Laure Delaval, José Timsit, Bertrand Knebelmann, Fabiola Terzi, Tarika Mahal, Yizhou Zhu, Philip G. Morgan, Margaret M. Sedensky, Matt Kaeberlein, Christophe Legendre, Yousin Suh, Guillaume Canaud
Journal: Kidney International (2018)
Association of Secondary Preventive Cardiovascular Treatment After Myocardial Infarction With Mortality Among Patients With Schizophrenia
Authors: Pirathiv Kugathasan, Henriette Thisted Horsdal, Jørgen Aagaard, Svend Eggert Jensen, Thomas Munk Laursen, René Ernst Nielsen
Journal: JAMA Psychiatry (2018)

Cardioprotective medication use is an important secondary preventive treatment after cardiovascular events. Patients with schizophrenia have excess cardiovascular morbidity and mortality, but no studies have investigated whether taking recommended cardioprotective medication can reduce this excess mortality.To assess the association of exposure to secondary cardiovascular treatment with all-cause mortality after myocardial infarction among patients with schizophrenia compared with the general population.This nationwide cohort study included individuals admitted with first-time myocardial infarction in Denmark from January 1, 1995, to December 31, 2015. The cohort was dichotomously divided by a diagnosis of schizophrenia. Data on the prescription of guideline-recommended cardioprotective medication, including antithrombotics, β-blockers, vitamin K antagonist, angiotensin-converting enzyme inhibitors, and statins, were obtained from the nationwide registries.Time exposed to cardioprotective medication.Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% CIs for the association between treatment exposure and all-cause mortality after myocardial infarction between patients with and without schizophrenia.The cohort included 105 018 patients with myocardial infarction, including 684 patients with schizophrenia (0.7%; 483 male [70.6%]; mean [SD] age at diagnosis, 57.3 [10.6] years) and 104 334 general population patients (99.3%; 73 454 male [70.4%]; mean [SD] age at diagnosis, 61.0 [10.6] years), with a total follow-up of 796 435 person-years and 28 059 deaths. Patients diagnosed with schizophrenia who did not receive cardioprotective treatment had the highest mortality rate (HR, 8.78; 95% CI, 4.37-17.64) compared with the general population treated, with treated patients diagnosed with schizophrenia having an increased HR of 1.97 (95% CI, 1.25-3.10). The analyses of the associations of different cardiac therapy strategies with mortality rates revealed that patients with schizophrenia who were treated with any combination of triple therapy had mortality rates similar to those observed in the general population (HR, 1.05; 95% CI, 0.43-2.52) in the multivariable analysis.Cardioprotective medication after myocardial infarction should be carefully managed to improve prognosis. The study results suggest that some of the increased cardiac mortality among patients with schizophrenia can be reduced if these patients are efficiently administered combinations of secondary preventive treatments after cardiac events.
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Authors: Maura L Gillison, Andy M Trotti, Jonathan Harris, Avraham Eisbruch, Paul M Harari, David J Adelstein, Richard C K Jordan, Weiqiang Zhao, Erich M Sturgis, Barbara Burtness, John A Ridge, Jolie Ringash, James Galvin, Min Yao, Shlomo A Koyfman, Dukagjin M Blakaj, Mohammed A Razaq, A Dimitrios Colevas, Jonathan J Beitler, Christopher U Jones, Neal E Dunlap, Samantha A Seaward, Sharon Spencer, Thomas J Galloway, Jack Phan, James J Dignam, Quynh Thu Le
Journal: The Lancet (2018)
Topoisomerase 1B poisons: Over a half‐century of drug leads, clinical candidates, and serendipitous discoveries
Authors: Maris A. Cinelli
Journal: Medicinal Research Reviews (2018)

Abstract Topoisomerases are DNA processing enzymes that relieve supercoiling (torsional strain) in DNA, are necessary for normal cellular division, and act by nicking (and then religating) DNA strands. Type 1B topoisomerase (Top1) is overexpressed in certain tumors, and the enzyme has been extensively investigated as a target for cancer chemotherapy. Various chemical agents can act as “poisons” of the enzyme’s religation step, leading to Top1‐DNA lesions, DNA breakage, and eventual cellular death. In this review, agents that poison Top1 (and have thus been investigated for their anticancer properties) are surveyed, including natural products (such as camptothecins and indolocarbazoles), semisynthetic camptothecin and luotonin derivatives, and synthetic compounds (such as benzonaphthyridines, aromathecins, and indenoisoquinolines), as well as targeted therapies and conjugates. Top1 has also been investigated as a therapeutic target in certain viral and parasitic infections, as well as autoimmune, inflammatory, and neurological disorders, and a summary of literature describing alternative indications is also provided. This review should provide both a reference for the medicinal chemist and potentially offer clues to aid in the development of new Top1 poisons.
Abstract 11290: Free Thyroxine (fT4) Within the Reference (‘Normal’) Range Predicts Risk of Atrial Fibrillation
Authors: Jeffrey L Anderson, Victoria Jacobs, Heidi T May, Tami L Bair, Donald L Lappé, Joseph B Muhlestein, Kirk U Knowlton, T J Bunch
Journal: Circulation (2018)

Background: Hyperthyroidism, defined by elevated thyroid hormones, is a known precipitating factor for atrial fibrillation (AF). The prospective Rotterdam Study recently reported an increased risk ...
Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy
Authors: Marcio H. Miname, Marcio Sommer Bittencourt, Sérgio R. Moraes, Rômulo I.M. Alves, Pamela R.S. Silva, Cinthia E. Jannes, Alexandre C. Pereira, José E. Krieger, Khurram Nasir, Raul D. Santos
Journal: JACC. Cardiovascular imaging (2018)
Successes and Challenges in Precision Medicine in Psychiatry
Authors: Edwin J. C. G. van den Oord, Robin F. Chan, Karolina A. Aberg
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
A Study of the cytotoxic effects of cetuximab and the interaction with a selective Cox-2 inhibitor (Celecoxib) in breast cancer cell lines.
Authors: Osama Halaweh, Adli Yakan, Catherine L. Lobocki, Anibal Drelichman
Journal: Cancer Research (2006)

5087  OBJECTIVES: Direct modulation of signal transduction pathways by Epidermal Growth Factor (EGF) and its family members, as well as their indirect regulation by other unrelated mediators are critical during cancer cells development. In addition, there has been a growing body of data indicating a role of Cyclooxygenase (COX) -2 in carcinogenesis. The purpose of this study was to assess the antiproliferative effect of Cetuximab, a monoclonal antibody that binds the extracellular domain of the EGF receptor (EGFR), and to evaluate the interaction between Cetuximab and Celecoxib. METHODS: Increasing doses of Cetuximab (0.5 100 mg/ml) and Celecoxib (5 40 mM) were tested alone and in combination against human breast cancer cell lines, including BT20 which has an amplification of the EGFR, and MCF-7 which expresses low levels of the receptor. Inhibition of cell growth after 7 days of treatment was assessed by the MTT colorimetric assay, while apoptosis was detected using an in situ DNA Fragmentation Detection kit. RESULTS: Cetuximab inhibited the growth of BT20 by as much as 35% compared to only 15% in the MCF-7 cell line (p
Re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410–8
Authors: Ashwin Shinde, Richard Li, Arya Amini, Scott Glaser
Journal: European Urology (2018)
A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies
Authors: Wojciech Jurczak, Simon Rule, William Townsend, David Tucker, Barbara Sarholz, Jürgen Scheele, John G. Gribben, Pier Luigi Zinzani
Journal: Blood (2018)
Просвітянка Ольга Косач-Кривинюк — земський лікар на Катеринославщині (до 140-річчя від дня народження)
Authors: M.P. Chaban, Z.I. Shevtsova, V.V. Gaponov
Journal: GASTROENTEROLOGY (2018)

Розглянуто зв’язок представників родини Косачів-Кривинюків з Катеринославом. Висвітлена роль однієї з перших жінок — земських лікарів на Катеринославщині Ольги Косач-Кривинюк (молодшої сестри Лесі Українки) в наданні медичної допомоги населенню. Показано внесок Ольги Косач-Кривинюк у розвиток національної культури, літератури та просвітницького руху на Катеринославщині.